# The DART DELIVER-02 Study

> **NCT07217379** · PHASE1 · RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 24 (estimated)

## Conditions studied

- HIV (Human Immunodeficiency Virus)

## Interventions

- **DRUG:** MGD020
- **DRUG:** MGD014
- **DRUG:** Vorinostat
- **OTHER:** Temporary treatment interruption

## Key facts

- **NCT ID:** NCT07217379
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-02
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217379, "The DART DELIVER-02 Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07217379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*